Roivant Sciences ROIV
NASDAQ ROIV
$37.45 +0.65 (+1.77%)
At close: Oct 22, 2026 · 4:00 PM EDT

Roivant Sciences (ROIV) Long-Term Investments (2021)

Updated

Roivant Sciences' Long-Term Investments was $100.56 million in fiscal Q1 2022 (quarter ended Jun 30, 2021), unchanged from the prior quarter.

Analysis

Roivant Sciences (ROIV) Long-Term Investments (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 3.86 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 266.00 Mn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 1.22 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 69.00 Mn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 297.00 Mn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 1.56 Bn
10 Roivant Sciences 26.91 Bn 9.86 Bn 1.16 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 100.56 Mn
Mar 31, 2021 100.56 Mn
API Access

Roivant Sciences Long-Term Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-investments&ticker=ROIV&period=max&api_key=YOUR_API_KEY